Atlas Trials

Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo in Adult Volunteers

Clinical trial NCT05625477 · COMPLETED

Trial details

NCT number
NCT05625477
Sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Tetanus
Start date
2022-04-18
Primary completion
2022-05-29
Enrollment
240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.